Quick Answer
Sensei Biotherapeutics, Inc. reported Net Income Loss of -$21.09 million for the year ending 2025.
- Sensei Biotherapeutics, Inc. showed an increase of +30.1% in Net Income Loss from 2024 to 2025.
- This data is from Sensei Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$4.69 million | Q2 2020: -$4.91 million | Q3 2020: -$5.37 million | Q1 2021: -$7.97 million | Q2 2021: -$9.77 million | Q3 2021: -$9.69 million | Q1 2022: -$12.41 million | Q2 2022: -$10.54 million | Q3 2022: -$13.42 million | Q1 2023: -$10.18 million | Q2 2023: -$9.39 million | Q3 2023: -$7.12 million | Q1 2024: -$7.99 million | Q2 2024: -$7.14 million | Q3 2024: -$7.25 million | Q1 2025: -$6.86 million | Q2 2025: -$4.94 million | Q3 2025: -$4.57 million.
- Over the full 6 years of available data (2020 to 2025), Sensei Biotherapeutics, Inc.'s Net Income Loss has declined by 4.9%.
- Historical annual values: Fiscal year 2025: -$21.09 million | Fiscal year 2024: -$30.16 million | Fiscal year 2023: -$34.10 million | Fiscal year 2022: -$48.59 million | Fiscal year 2021: -$36.79 million | Fiscal year 2020: -$20.10 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: